Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04468971 · ClinicalTrials.gov registry record · Phase 1
REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia
A Phase 1 study of COVID-19 and ARDS, sponsored by Cellenkos.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT04468971: Completed Phase 1 study of COVID-19 and ARDS, sponsored by Cellenkos.
NCT04468971 is a Phase 1 study of COVID-19 and ARDS that has completed, run by Cellenkos. The registered enrollment target is 45 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04468971, a Phase 1 study of COVID-19 and ARDS, has completed, sponsored by Cellenkos.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
Primary Outcome
Regimen related ≥ grade 3 toxicity within 48 hours of first infusion (DLT)
Interventions
- DRUG Placebo
- BIOLOGICAL CK0802
Study Locations (5)
North Carolina
- University of North Carolina - Chapel Hill
- Wake Forest University - Winston-Salem
Maryland
- Johns Hopkins Hospital - Baltimore
New York
- Columbia University - New York
Texas
- Baylor College of Medicine, St Luke's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2021-10-22 |
| Phase | Phase 1 |
What the finished NCT04468971 record still lists
NCT04468971 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04468971 lists 5 locations in 4 states (North Carolina, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT04468971 about?
NCT04468971 is a clinical study titled "REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia". To assess the safety and efficacy of CK0802 in treatment of patients with COVID-19 induced moderate-to-severe PNA-ARDS.
What is the current status of trial NCT04468971?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2020-09-29. Estimated completion is 2021-10-22.
What conditions does trial NCT04468971 study?
This clinical trial studies the following conditions: COVID-19, ARDS.
What interventions are being tested in trial NCT04468971?
The interventions under investigation include: Placebo (DRUG), CK0802 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04468971?
This trial is sponsored by Cellenkos, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04468971 being conducted?
This trial has 5 study locations across Maryland, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04468971's enrollment target sits among peer trials
45 254th of 298 higher than 45 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI